SCHEDULE: Vanguard Group Exits Keros Therapeutics Stake

The Vanguard Group reported 0% beneficial ownership in Keros Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Keros Therapeutics Inc., reporting 0% beneficial ownership of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• In accordance with SEC Release No. 34-39538, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a procedural filing reflecting an internal organizational change at Vanguard, rather than a direct positive or negative statement about Keros Therapeutics' performance or prospects. The impact on Keros Therapeutics is neutral as it relates to Vanguard's reporting structure.

Future Outlook

The filing indicates that Vanguard's subsidiaries and/or business divisions will pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment, and will report beneficial ownership separately.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that this type of Schedule 13G amendment, reflecting a change in beneficial ownership due to internal organizational restructuring, is a common administrative occurrence for large, diversified asset managers like The Vanguard Group. It typically signifies a shift in reporting methodology rather than a fundamental change in investment strategy or a divestment from the underlying company by all Vanguard-managed funds.

Stakeholder Impact

• Shareholders of Keros Therapeutics Inc. should understand that while The Vanguard Group, Inc. itself reports 0% beneficial ownership, underlying investment by various Vanguard-managed funds may still exist and will be reported by individual subsidiaries or business divisions.

Next Steps

• Vanguard's subsidiaries and/or business divisions will report their beneficial ownership of Keros Therapeutics Inc. securities separately.

Key Dates

Keywords

Keros Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, equity stake, SEC filing, investment management